You are here

SMA

Biogen Reports New Spinraza Data in SMA

Biogen Reports New Spinraza Data in SMA

Global Genes

Flag link:

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche

Pharmaforum

Flag link:

Scholar Rock eyes phase 3 after confirming effects of SMA drug

Scholar Rock eyes phase 3 after confirming effects of SMA drug

Fierce Biotech

clinical trials

Flag link:

Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's

Years after a major trial setback, Novartis switches gears with SMA drug. This time they're trying it for Huntington's

Endpoints

Huntington's disease

Flag link:

Biogen finally culls MS dud opicinumab, adds SMA gene therapy to the garbage heap

Biogen finally culls MS dud opicinumab, adds SMA gene therapy to the garbage heap

Fierce Biotech

Flag link:

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

From no drugs to 3: Patients with spinal muscular atrophy now face hard choices

BioPharma Dive

spinal muscular atrophy

Flag link:

FDA sets back Novartis plans to expand use of SMA gene therapy

FDA sets back Novartis plans to expand use of SMA gene therapy

BioPharma Dive

clinical trials

Flag link:

Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

Biogen to Run Phase IV SMA Trial: “I Want to Optimize Their Life.”

BioSpace

spinal muscular atrophy

clinical trials

Flag link:

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

Xconomy

spinal muscular atrophy

Flag link:

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

Biogen to launch Phase IV study of spinal muscular atrophy drug in post-gene therapy patients

MedCity News

clinical trials

spinal muscular atrophy

Flag link:

OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020

OptumRx: The 3 drugs that will have the biggest impact on payers, patients in 2020

Beckers Hospital Review

PTC Therapeutics

Duchenne Muscular Dystrophy

triple negative breast cancer

Flag link:

Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients

Biogen’s Spinraza Shows Sustained Benefit for Pre-Symptomatic SMA Patients

BioSpace

clinical trials

Flag link:

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy

New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy

Fierce Pharma

spinal muscular atrophy

Flag link:

Roche shares SMA data ahead of scrap with Biogen, Novartis

Roche shares SMA data ahead of scrap with Biogen, Novartis

Fierce Biotech

spinal muscular atrophy

clinical trials

Flag link:

Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

Roche’s risdiplam delay a relief for SMA rivals Biogen and Novartis—for now: analyst

Fierce Pharma

Flag link:

FDA delays decision on Roche spinal muscular atrophy drug

FDA delays decision on Roche spinal muscular atrophy drug

Biopharma Dive

Flag link:

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy

Xconomy

Flag link:

Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents

Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents

Fierce Pharma

Flag link:

Novartis publishes long-term data from SMA gene therapy

Novartis publishes long-term data from SMA gene therapy

Pharmaforum

Flag link:

Novartis faces criticism over Zolgensma ‘health lottery’

Novartis faces criticism over Zolgensma ‘health lottery’

PM Live

Flag link:

Pages